Home/Filings/4/0001104659-26-004659
4//SEC Filing

HENDERSON MICHAEL THOMAS 4

Accession 0001104659-26-004659

CIK 0001974640other

Filed

Jan 15, 7:00 PM ET

Accepted

Jan 16, 8:00 PM ET

Size

15.3 KB

Accession

0001104659-26-004659

Insider Transaction Report

Form 4
Period: 2026-01-14
HENDERSON MICHAEL THOMAS
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-01-14$78.64/sh1,440$113,2421,211,547 total
  • Sale

    Common Stock

    [F1][F3]
    2026-01-14$79.82/sh8,476$676,5541,203,071 total
  • Sale

    Common Stock

    [F1][F4]
    2026-01-14$81.00/sh2,374$192,2941,200,697 total
  • Sale

    Common Stock

    [F1][F5]
    2026-01-14$82.41/sh1,854$152,7881,198,843 total
  • Sale

    Common Stock

    [F1][F6]
    2026-01-14$83.16/sh5,386$447,9001,193,457 total
  • Sale

    Common Stock

    [F1][F7]
    2026-01-14$83.79/sh470$39,3811,192,987 total
Footnotes (7)
  • [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
  • [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.16 to $79.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.28 to $80.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.69 to $81.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F5]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.70 to $82.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F6]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.71 to $83.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F7]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.73 to $83.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Matthew Batters, as attorney-in-fact for Michael Henderson|2026-01-16

Issuer

Apogee Therapeutics, Inc.

CIK 0001974640

Entity typeother

Related Parties

1
  • filerCIK 0001779990

Filing Metadata

Form type
4
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 8:00 PM ET
Size
15.3 KB